Protection against adriamycin (doxorubicin)-induced toxicity in mice by several clinically used drugs.
Protective effects of clinically used drugs against adriamycin (ADM)-induced toxicity were studied in ICR mice. The control mice, which were administered 15 mg/kg of ADM twice, survived 7.48 +/- 1.99 days (mean +/- S.D.). The survival times of mice treated with the following drugs, expressed as a percent of that of the control group, were 293.6% for coenzyme Q10 (Co Q10, 2 mg/kg), 402.2% for dextran sulfate (MDS, 300 mg/kg), 121.6% for flavin adenine dinucleotide (20 mg/kg), 236.3% for adenosine triphosphate disodium (50 mg/kg), 213.7% for reduced glutathione (100 mg/kg), 121.6% for phytonadione (50 mg/kg), 155.2% for inositol nicotinate (Ino-N, 500 mg/kg), 335.5% for nicomol (1000 mg/kg), 157.5% for nicardipine (10 mg/kg) and 123.3% for dipyridamol (50 mg/kg). Anti-hyperlipemic agents such as MDS, nicomol, Ino-N and Co Q10 strongly protected against the ADM-induced toxicity, and the mice administered these drugs lived significantly longer than the control mice. The mechanism of the protective effect was discussed.
D000818:Animals; D003067:Coenzymes; D016264:Dextran Sulfate; D003911:Dextrans / Q000494:pharmacology; D004317:Doxorubicin / Q000633:toxicity*; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000494:pharmacology
D003067:Coenzymes; D003911:Dextrans; D000960:Hypolipidemic Agents; D014451:Ubiquinone; D004317:Doxorubicin; D016264:Dextran Sulfate; C024989:coenzyme Q10